APA

Lincoff A. M., Tardif J., Neal B., Nicholls S. J., Rydén L., Schwartz G. G., Malmberg K., Buse J. B., Henry R. R., Wedel H., Weichert A., Cannata R. & Grobbee D. E. (20131211). Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. : American heart journal.

Chicago

Lincoff A Michael, Tardif Jean-Claude, Neal Bruce, Nicholls Stephen J, Rydén Lars, Schwartz Gregory G, Malmberg Klas, Buse John B, Henry Robert R, Wedel Hans, Weichert Arlette, Cannata Ruth and Grobbee Diederick E. 20131211. Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. : American heart journal.

Harvard

Lincoff A. M., Tardif J., Neal B., Nicholls S. J., Rydén L., Schwartz G. G., Malmberg K., Buse J. B., Henry R. R., Wedel H., Weichert A., Cannata R. and Grobbee D. E. (20131211). Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. : American heart journal.

MLA

Lincoff A Michael, Tardif Jean-Claude, Neal Bruce, Nicholls Stephen J, Rydén Lars, Schwartz Gregory G, Malmberg Klas, Buse John B, Henry Robert R, Wedel Hans, Weichert Arlette, Cannata Ruth and Grobbee Diederick E. Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. : American heart journal. 20131211.